Rajavelu Esther 4
4 · Spero Therapeutics, Inc. · Filed Feb 9, 2026
Research Summary
AI-generated summary of this filing
Spero (SPRO) CEO Esther Rajavelu Sells Shares
What Happened
Esther Rajavelu — listed as Chief Executive Officer (also noted as Chief Financial Officer and Chief Business Officer) — reported two sales on 2026-02-06 disposing of a total 87,917 shares of Spero Therapeutics (SPRO). The sales were: 37,101 shares at $2.36 each for $87,558, and 50,816 shares at $2.36 each for $119,926, for combined proceeds of about $207,484. These were sales (S) and, per the filing footnote, were automatic "sell-to-cover" transactions to satisfy tax withholding on vested RSUs rather than discretionary trades.
Key Details
- Transaction dates and prices: 2026-02-06 — 37,101 shares @ $2.36; 50,816 shares @ $2.36.
- Total proceeds: ~$207,484.
- Footnote: Sale was to cover tax withholding on RSU vesting (automatic "sell-to-cover"); not a discretionary sale.
- Shares owned after transaction: Not specified in the filing.
- Filing date: 2026-02-09; the Form 4 was filed promptly following the 2026-02-06 transactions (no late filing indicated).
Context
Sell-to-cover transactions are common when restricted stock units vest and the holder owes taxes; they typically do not signal a deliberate decision to reduce an insider’s exposure. For retail investors, outright purchases by insiders tend to be more informative about confidence than routine tax-related sales.
Insider Transaction Report
- Sale
Common Stock
[F1]2026-02-06$2.36/sh−37,101$87,558→ 1,062,907 total - Sale
Common Stock
[F1]2026-02-06$2.36/sh−50,816$119,926→ 1,012,091 total
Footnotes (1)
- [F1]Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.